Cargando…

Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development

The International Council for Harmonisation (ICH) E6(R2) (International Council for Harmonisation (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 5 Dec 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhagat, Ruma, Bojarski, Lukasz, Chevalier, Soazig, Görtz, Dagmar R., Le Meignen, Stéphanie, Makowski, Marcin, Nadolny, Patrick, Pillwein, Marion, Suprin, Melissa, Turri, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864825/
https://www.ncbi.nlm.nih.gov/pubmed/32885397
http://dx.doi.org/10.1007/s43441-020-00209-0
_version_ 1783647727546007552
author Bhagat, Ruma
Bojarski, Lukasz
Chevalier, Soazig
Görtz, Dagmar R.
Le Meignen, Stéphanie
Makowski, Marcin
Nadolny, Patrick
Pillwein, Marion
Suprin, Melissa
Turri, Sabine
author_facet Bhagat, Ruma
Bojarski, Lukasz
Chevalier, Soazig
Görtz, Dagmar R.
Le Meignen, Stéphanie
Makowski, Marcin
Nadolny, Patrick
Pillwein, Marion
Suprin, Melissa
Turri, Sabine
author_sort Bhagat, Ruma
collection PubMed
description The International Council for Harmonisation (ICH) E6(R2) (International Council for Harmonisation (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 5 Dec 2019) introduced Quality Tolerance Limits (QTLs) to the industry, and in doing so, modernized quality control for clinical trials. QTLs provide measured feedback on clinical trial parameters previously only used by statistical and clinical functions to track trial progress toward endpoints. Elevating these measures as part of the Quality Management System (QMS) provides greater visibility across clinical trial functions and the enterprise as well as to measures that are important indicators of the state of participant protection and reliability of trial results. In support of this new requirement, TransCelerate developed a framework to guide industry sponsors and their agents in implementing QTLs. This QTL Framework is intended to aid industry’s ability to improve the quality of clinical research through the implementation of QTLs in a way that helps protect trial participants and reliability of trial results while meeting Health Authority (HA) expectations. The framework is intended to maximize efficiency and minimize confusion in the implementation of QTLs. The framework includes proposed approaches for implementation of QTLs for a clinical trial as defined in Section 5.0.4 and 5.0.7 of ICH E6(R2) (International Council for Harmonisation (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 5 Dec 2019) and considerations for setting thresholds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s43441-020-00209-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7864825
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78648252021-02-16 Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development Bhagat, Ruma Bojarski, Lukasz Chevalier, Soazig Görtz, Dagmar R. Le Meignen, Stéphanie Makowski, Marcin Nadolny, Patrick Pillwein, Marion Suprin, Melissa Turri, Sabine Ther Innov Regul Sci Analytical Report The International Council for Harmonisation (ICH) E6(R2) (International Council for Harmonisation (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 5 Dec 2019) introduced Quality Tolerance Limits (QTLs) to the industry, and in doing so, modernized quality control for clinical trials. QTLs provide measured feedback on clinical trial parameters previously only used by statistical and clinical functions to track trial progress toward endpoints. Elevating these measures as part of the Quality Management System (QMS) provides greater visibility across clinical trial functions and the enterprise as well as to measures that are important indicators of the state of participant protection and reliability of trial results. In support of this new requirement, TransCelerate developed a framework to guide industry sponsors and their agents in implementing QTLs. This QTL Framework is intended to aid industry’s ability to improve the quality of clinical research through the implementation of QTLs in a way that helps protect trial participants and reliability of trial results while meeting Health Authority (HA) expectations. The framework is intended to maximize efficiency and minimize confusion in the implementation of QTLs. The framework includes proposed approaches for implementation of QTLs for a clinical trial as defined in Section 5.0.4 and 5.0.7 of ICH E6(R2) (International Council for Harmonisation (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 5 Dec 2019) and considerations for setting thresholds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s43441-020-00209-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-09-03 2021 /pmc/articles/PMC7864825/ /pubmed/32885397 http://dx.doi.org/10.1007/s43441-020-00209-0 Text en © TransCelerate BioPharma Inc. 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Analytical Report
Bhagat, Ruma
Bojarski, Lukasz
Chevalier, Soazig
Görtz, Dagmar R.
Le Meignen, Stéphanie
Makowski, Marcin
Nadolny, Patrick
Pillwein, Marion
Suprin, Melissa
Turri, Sabine
Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title_full Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title_fullStr Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title_full_unstemmed Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title_short Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development
title_sort quality tolerance limits: framework for successful implementation in clinical development
topic Analytical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864825/
https://www.ncbi.nlm.nih.gov/pubmed/32885397
http://dx.doi.org/10.1007/s43441-020-00209-0
work_keys_str_mv AT bhagatruma qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT bojarskilukasz qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT chevaliersoazig qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT gortzdagmarr qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT lemeignenstephanie qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT makowskimarcin qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT nadolnypatrick qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT pillweinmarion qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT suprinmelissa qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment
AT turrisabine qualitytolerancelimitsframeworkforsuccessfulimplementationinclinicaldevelopment